Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cancers|February 10, 2021
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future PerspectivesRobert Jenke, Nina Reßing, Finn K Hansen, et al.Anticancer Research|December 1, 2021
The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer CellsKazuki Okubo, Nina REßING, Wolfgang A Schulz, et al.Anticancer Research|June 4, 2021
Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer CellsKazuki Okubo, Makoto Isono, Takako Asano, et al.Archiv Der Pharmazie|August 11, 2025
Exploration of Fluorinated Peptoid-Based Histone Deacetylase Inhibitors as Dual-Stage Antiplasmodial AgentsNina Reßing, Daniel Stopper, Thomas Martin Schäfer, et al.Journal of Medicinal Chemistry|October 2, 2023
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase <b>6</b>Beate König, Paris R Watson, Nina Reßing, et al.Medchemcomm|August 9, 2019
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activityNina Reßing, Viktoria Marquardt, Christoph G W Gertzen, et al.Journal of Medicinal Chemistry|October 27, 2018
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome InhibitorSanil Bhatia, Viktoria Krieger, Michael Groll, et al.Journal of Medicinal Chemistry|August 18, 2020
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping GroupsNina Reßing, Melf Sönnichsen, Jeremy D Osko, et al.Journal of Medicinal Chemistry|November 9, 2022
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute LeukemiaNina Reßing, Julian Schliehe-Diecks, Paris R Watson, et al.Pageof 1